Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients
Treated With MATRix Regimen Are Similar to IELSG32 Trial
Results

J 2025

Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results

VODICKA, Prokop; Andrea JANÍKOVÁ; David BELADA; Veronika HANACKOVA; Heidi MOCIKOVA et al.

Základní údaje

Originální název

Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results

Autoři

Vydání

Hematological Oncology, Hoboken, WILEY-BLACKWELL, 2025, 0278-0232

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.900 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

autologous stem cell transplantation; IELSG32 trial; MATRix regimen; primary central nervous system lymphoma; real-world results

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 5. 11. 2025 12:55, Mgr. Tereza Miškechová

Anotace

V originále

Primary central nervous system lymphomas (PCNSL) are rare malignancies with poor survival outcomes. The IELSG32 trial demonstrated efficacy of MATRix chemoimmunotherapy followed by autologous stem cell transplantation (auto-SCT) in PCNSL patients aged <= 70 years with a performance status (PS) ECOG <= 3. However, long-term real-world results of MATRix/auto-SCT therapy remain limited. This analysis, with a median follow-up of 52 months, aimed to evaluate the outcomes of MATRix-treated PCNSL patients in clinical practice. From 2015 to 2022, 280 PCNSL patients who received systemic therapy were identified in the NiHiL project (NCT03199066). Eighty-eight individuals treated with MATRix entered the analysis. Endpoints included efficacy and safety of induction and consolidation therapy. Seventy-eight patients who met key IELSG32 inclusion criteria (age <= 65 years and PS ECOG <= 3, or age 66-70 years and PS ECOG <= 2) achieved an overall response rate of 82% (complete remission rate 58%) following MATRix regimen. After median follow-up of 52 months, 4-year progression-free survival and overall survival (OS) rates were 53% and 55%, respectively. Forty-six (59%) patients completed MATRix treatment, and 32 (41%) discontinued induction therapy (15 toxicity, 11 infections, 5 progressive diseases, 1 refusal). The treatment-related mortality was 8%. Among 67 patients with responsive/stable disease, 50 underwent consolidation with whole-brain radiotherapy (WBRT, n = 13) or auto-SCT (n = 37). No significant survival differences were observed between WBRT and auto-SCT (4-year OS 84% vs. 74%, HR 0.61, 95% CI 0.16-2.29, p = 0.467). Long-term real-world outcomes of MATRix/auto-SCT therapy are comparable to IELSG32, supporting its use in younger, fit PCNSL patients.

Citovat

VODICKA, Prokop; Andrea JANÍKOVÁ; David BELADA; Veronika HANACKOVA; Heidi MOCIKOVA; Juraj DURAS; Katerina STEINEROVA; Katerina BENESOVA; Eva KONIROVA; Tomas PROCHAZKA; Kamila POLGAROVA; Michal MASAR; Jitka DLOUHA; Petra BLAHOVCOVA a Marek TRNENY. Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results. Hematological Oncology. Hoboken: WILEY-BLACKWELL, 2025, roč. 43, č. 6, s. 1-8. ISSN 0278-0232. Dostupné z: https://doi.org/10.1002/hon.70142.

@article{2530823,
   author = {Vodicka, Prokop and Janíková, Andrea and Belada, David and Hanackova, Veronika and Mocikova, Heidi and Duras, Juraj and Steinerova, Katerina and Benesova, Katerina and Konirova, Eva and Prochazka, Tomas and Polgarova, Kamila and Masar, Michal and Dlouha, Jitka and Blahovcova, Petra and Trneny, Marek},
   article_location = {Hoboken},
   article_number = {6},
   doi = {https://doi.org/10.1002/hon.70142},
   keywords = {autologous stem cell transplantation; IELSG32 trial; MATRix regimen; primary central nervous system lymphoma; real-world results},
   language = {eng},
   issn = {0278-0232},
   journal = {Hematological Oncology},
   title = {Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/hon.70142},
   volume = {43},
   year = {2025}
}

TY  - JOUR
ID  - 2530823
AU  - Vodicka, Prokop - Janíková, Andrea - Belada, David - Hanackova, Veronika - Mocikova, Heidi - Duras, Juraj - Steinerova, Katerina - Benesova, Katerina - Konirova, Eva - Prochazka, Tomas - Polgarova, Kamila - Masar, Michal - Dlouha, Jitka - Blahovcova, Petra - Trneny, Marek
PY  - 2025
TI  - Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results
JF  - Hematological Oncology
VL  - 43
IS  - 6
SP  - 1-8
EP  - 1-8
PB  - WILEY-BLACKWELL
SN  - 02780232
KW  - autologous stem cell transplantation
KW  - IELSG32 trial
KW  - MATRix regimen
KW  - primary central nervous system lymphoma
KW  - real-world results
UR  - https://onlinelibrary.wiley.com/doi/10.1002/hon.70142
N2  - Primary central nervous system lymphomas (PCNSL) are rare malignancies with poor survival outcomes. The IELSG32 trial demonstrated efficacy of MATRix chemoimmunotherapy followed by autologous stem cell transplantation (auto-SCT) in PCNSL patients aged <= 70 years with a performance status (PS) ECOG <= 3. However, long-term real-world results of MATRix/auto-SCT therapy remain limited. This analysis, with a median follow-up of 52 months, aimed to evaluate the outcomes of MATRix-treated PCNSL patients in clinical practice. From 2015 to 2022, 280 PCNSL patients who received systemic therapy were identified in the NiHiL project (NCT03199066). Eighty-eight individuals treated with MATRix entered the analysis. Endpoints included efficacy and safety of induction and consolidation therapy. Seventy-eight patients who met key IELSG32 inclusion criteria (age <= 65 years and PS ECOG <= 3, or age 66-70 years and PS ECOG <= 2) achieved an overall response rate of 82% (complete remission rate 58%) following MATRix regimen. After median follow-up of 52 months, 4-year progression-free survival and overall survival (OS) rates were 53% and 55%, respectively. Forty-six (59%) patients completed MATRix treatment, and 32 (41%) discontinued induction therapy (15 toxicity, 11 infections, 5 progressive diseases, 1 refusal). The treatment-related mortality was 8%. Among 67 patients with responsive/stable disease, 50 underwent consolidation with whole-brain radiotherapy (WBRT, n = 13) or auto-SCT (n = 37). No significant survival differences were observed between WBRT and auto-SCT (4-year OS 84% vs. 74%, HR 0.61, 95% CI 0.16-2.29, p = 0.467). Long-term real-world outcomes of MATRix/auto-SCT therapy are comparable to IELSG32, supporting its use in younger, fit PCNSL patients.
ER  -

VODICKA, Prokop; Andrea JANÍKOVÁ; David BELADA; Veronika HANACKOVA; Heidi MOCIKOVA; Juraj DURAS; Katerina STEINEROVA; Katerina BENESOVA; Eva KONIROVA; Tomas PROCHAZKA; Kamila POLGAROVA; Michal MASAR; Jitka DLOUHA; Petra BLAHOVCOVA a Marek TRNENY. Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results. \textit{Hematological Oncology}. Hoboken: WILEY-BLACKWELL, 2025, roč.~43, č.~6, s.~1-8. ISSN~0278-0232. Dostupné z: https://doi.org/10.1002/hon.70142.

Přehled o publikaci